Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 16/20 | 0.80 |
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | BRD4 | O60885 | 4/20 | 0.55 |
| ▸ | JAK1 | P23458 | 2/20 | 0.55 |
| ▸ | BRD2 | P25440 | 2/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16571082 | 0.93 | FGFR4 (0.70) | FGFR4JAK2BRD4JAK1BRD2 | |
| SCHEMBL16570303 | 0.89 | FGFR4 (0.66) | FGFR4JAK2BRD4JAK1BRD2 | |
| SCHEMBL16570912 | 0.89 | FGFR4 (0.67) | FGFR4JAK2BRD4JAK1BRD2 | |
| SCHEMBL16570509 | 0.88 | FGFR4 (0.63) | FGFR4JAK2BRD4JAK1BRD2 | |
| SCHEMBL16570890 | 0.88 | FGFR4 (0.73) | FGFR4 | |
| SCHEMBL16570888 | 0.88 | FGFR4 (0.73) | FGFR4 | |
| SCHEMBL16570963 | 0.87 | FGFR4 (0.79) | FGFR4JAK2BRD4JAK1BRD2 | |
| SCHEMBL16571022 | 0.87 | FGFR4 (0.82) | FGFR4JAK2BRD4JAK1BRD2 | |
| SCHEMBL16571226 | 0.87 | FGFR4 (0.61) | FGFR4JAK2BRD4JAK1BRD2 | |
| SCHEMBL16570402 | 0.86 | FGFR4 (0.74) | FGFR4JAK2BRD4JAK1BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | FGFR4 385/4885JAK2 9/4885BRD4 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.